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Abstract
Objective: Ghrelin is a 28-amino acid orexigenic peptide synthesized mainly in the stomach. Acute administration of ghrelin
has been found to decrease insulin secretion. However, little data is available regarding whether ghrelin contributes to the
long-term regulation of insulin resistance at the population level. The aim of this study is to investigate the association
between circulating ghrelin and insulin resistance in a large population based study.
Design: A total of 2082 CODING study (Complex Diseases in the Newfoundland population: Environment and Genetics)
subjects were assessed. Subjects were of at least third generation Newfoundland descent, between the ages of 20 and 79
years, and had no serious metabolic, cardiovascular, or endocrine diseases. Ghrelin was measured with an Enzyme
Immunoassay method. Insulin and fasting glucose were measured by Immulite 2500 autoanalyzer and Lx20 clinical
chemistry analyzer, respectively. Homeostatic Model Assessment of b cell function (HOMA-b) and Insulin Resistance (HOMA-
IR) and Quantitative Insulin-sensitivity Check Index (QUICKI) were used for measurement of insulin resistance.
Results: Partial correlation analyses showed a significant negative correlation between circulating ghrelin and insulin level
and insulin resistance in the entire cohort and also in men and women separately. The aforementioned correlation was
independent of age, percentage of trunk fat and HDL-cholesterol. According to menopausal status, only pre-menopausal
women revealed negative correlations.
Conclusion: Our results suggest that except for postmenopausal women, high circulating ghrelin level is associated with
lower insulin resistance in the general population.
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Introduction
Diabetes mellitus is one of the most common chronic diseases
worldwide. The estimated number of diabetic patients in 2010 was
366 million globally and it is predicted that this number will
increase to 552 million by 2030 [1]. Type 2 diabetes is the most
common type of diabetes. As a complex disease, both genetic and
environmental factors are involved in development of this disease
[2]. Pathogenesis of type 2 diabetes is complicated by several
factors and insulin resistance, insulin deficiency, or both may
contribute to this disease [3].
The gastrointestinal tract (gut) is the largest endocrine organ of
the body. The gut produces hormones that have important roles in
controlling body weight and energy homeostasis through the gut-
brain axis [4,5]. Previous studies showed that gastric bypass
surgery results in a significant improvement of type 2 diabetes, and
gut hormones play a role in this remission [6].
Ghrelin is a 28 amino acid orexigenic peptide synthesized
mainly in stomach [7]. Circulating levels increase during fasting
and decrease rapidly after a meal, so ghrelin has a role in acute
changes in energy balance and satiety [8]. Ghrelin is a pleiotropic
hormone that can influence different metabolic functions such as
increasing food intake, inducing positive energy balance, promot-
ing enlargement of adipocytes and also releasing growth hormone
[9,10]. Function of ghrelin on energy metabolism has been
thought to be mediated by the central mechanisms, such as
activation of the ghrelin receptor in the hypothalamic neuropep-
tide Y and agouti-related protein (NPY/AgRP) neurons [11].
Recently accumulating data suggest that ghrelin has central and
peripheral effects on glucose regulation and insulin level [12,13].
In rats ghrelin inhibits insulin secretion and stimulates glucagon
secretion from pancreatic islets [14]. Infusion of exogenous ghrelin
in healthy humans decreases glucose stimulated insulin secretion
[12,15,16]. Moreover, it was shown that fasting ghrelin in type 2
diabetic patients is lower than in those who do not have diabetes
[17]. Adolescent obese polycystic ovarian syndrome (which is
characterized by insulin resistance) patients had lower ghrelin level
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compared with lean subjects and ghrelin was negatively correlated
with Homeostatic Model Assessment of Insulin Resistance
(HOMA-IR) [18].
On the other hand, no association was found between insulin
sensitivity measured with euglycemic hyperinsulinemic clamp and
ghrelin level in men [19]. In a prospective follow up study no
significant difference was found between the ghrelin levels of
subjects who had normal glucose tolerance and those who
developed impaired fasting glucose, impaired glucose tolerance
and type 2 diabetes mellitus [20].
Because of the controversy of the data regarding the effect of
ghrelin on insulin resistance we designed the present study to
investigate the association between ghrelin and insulin resistance
in a large population based study: the CODING study (The




A total of 2082 subjects (1582 women and 500 men) were
enrolled from the ongoing nutrigenomics CODING study [21].
Volunteers were 1) between the ages of 20 and 79 years old; 2) of
at least third generation Newfoundland descent 3) without any
serious metabolic, cardiovascular, or endocrine diseases and 4)
females were not pregnant at the time of the study.
Serum Measurement
Venous blood samples were drawn from all volunteers following
a 12 hour fasting period. Blood was collected into tubes with
EDTA for plasma preparation and serum separator tubes (SST)
with clot activator. SST tubes were centrifuged at 3500 rpm for
10 min and EDTA tubes were centrifuged at 1300 g for 15 min to
separate serum and plasma respectively. Plasma and serum
samples were stored in a 280uC freezer.
Serum ghrelin was measured with an enzyme immunoassay
method (Human Acylated Ghrelin Enzyme Immunoassay Kit of
Spibio-bertin pharma) with the specifity of 100%, intra-assay
coefficient of variation (CV) of 5.7% and inter-assay CV of 17%.
Insulin and fasting glucose were measured by Immulite 2500
immunoassay analyzer and Lx20 clinical chemistry analyzer
(Beckman Coulter Inc.CA, USA) respectively.
Insulin Resistance Measurement
Although euglycemic hyperinsulinemic clamp is considered as
the gold standard for measurement of insulin resistance, previous
studies have shown that there is a high correlation between insulin
resistance measured with HOMA and QUICKI and one that is
measured by euglycemic clamp (R = 0.88, p,0.0001 and r = 0.69,
p,0.05) [22,23].
Homeostatic Model Assessment of b-cell function (HOMA-b)
and Insulin resistance (HOMA-IR) were calculated from fasting
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3 volunteers excluded from the study because of having fasting
glucose lower than 3.5 mmol/L that result in negative values for
HOMA-b.
Quantitative insulin-sensitivity check index (QUICKI) was the
other insulin sensitivity index that was used for measurement of
insulin sensitivity. It is determined by this mathematical equation
[24]:
QUICKI~ 1
, log fasting insulin mU=Lð Þ
z log







Subjects were divided into diabetic and non-diabetic groups
(based on the history and glucose level). According to the 2006
WHO criteria fasting glucose 7.0 mmol/L was considered as
diabetes [25]. 80 volunteers were in diabetic group and 2002
volunteers were in non-diabetic group.
Anthropometric and Body Composition Measurements
Anthropometric measurements were taken with participants
dressed in light clothing and without shoes. Standing height was
measured to the nearest 0.1 cm using a stadiometer. Body weight
was measured to the nearest 0.1 kg using a calibrated balance
scale (Health O Meter, Bridgeview, IL). BMI was calculated from
weight and height in kilograms per square meter. Waist
circumference was measured midway between the lowest rib and
iliac crest and hip circumference was measured at the widest point
over the greater trochanters using a flexible tape measure and they
were taken to the nearest millimeter.
Dual-energy X-Ray absorptiometry (DXA) Lunar Prodigy (GE
Medical Systems, Madison, WI) was used for measurement of
body composition.
Medication Use and Menopausal Status
Volunteers were divided to medication users and non-medica-
tion users. Medication users were those who reported using
prescribed medications or multivitamins regularly.
All of the female volunteers filled out a menstrual cycle and
menopausal status questionnaire and they were categorized as
premenopausal or postmenopausal based on this questionnaire.
Statistical Analysis
SPSS version 18.0 was used for all of the statistical analyses.
The summary statistics for continuous variables with normal
distribution were expressed as mean and standard deviation.
Non-normally distributed variables were expressed as median,
minimum and maximum. The level of statistical significance
was set at P value ,0.05. Logarithmic transformation was used
for the variables that did not have normal distribution (ghrelin,
insulin, HOMA-IR, HOMA-b, QUICKI and Triglyceride).
Analysis was performed on the entire cohort and also on men
and women separately. Women were also divided into
premenopausal and postmenopausal groups and the analysis
was conducted within these two groups. Pearson correlation
analyses were used to examine the relationship between various
potential factors that may have an effect on ghrelin or insulin
Ghrelin and Insulin Resistance
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sensitivity. Partial correlation analyses (controlling for age,
percentage of trunk fat and HDL-cholesterol ) were also
performed. General linear model (multivariative analyses) was
used to compare insulin resistance among the ghrelin groups, in
which ghrelin groups were set by ghrelin tertiles and the
covariates were age, trunk fat percentage and HDL-cholesterol.
All analyses were repeated excluding diabetic patients for
controlling the effect of blood glucose.
Ethical Considerations
The current study was approved by the Human Investigation
Committee of the Faculty of Medicine of Memorial University, St.
John’s, Newfoundland, Canada and all of the volunteers signed
informed consent to participate in the study.
Results
Physical and Biochemical Parameters
Mean and standard deviation of the parameters that were
normally distributed are summarized in Table 1. Ghrelin, insulin,
HOMA-IR, HOMA-b, QUICKI and Triglyceride were not
normally distributed. Median and range of these values are shown
in Table 2.
Association between Circulating Ghrelin Level and Insulin
Resistance
Partial correlation analyses after controlling for confounding
factors (age, percentage of trunk fat and HDL-cholesterol) showed
negative correlation between circulating ghrelin level and insulin,
HOMA-IR, HOMA-b and positive correlation between circulat-
ing ghrelin level and QUICKI. This association was not gender
specific and it was reported in both male and female subjects
(Table 3).
Influence of Menopause on the Relationship between
Ghrelin and Insulin Resistance
To explore the influence of menopause on the association
between ghrelin and insulin resistance, females were divided into
pre-menopausal and post-menopausal groups and partial correla-
tion analysis was performed after controlling for age, trunk fat
percentage and HDL-cholesterol. In premenopausal women, there
was a significant negative relationship between circulating ghrelin
level and insulin, HOMA-IR, HOMA-b and positive correlation
between circulating ghrelin and QUICKI whereas in post-
menopausal women, there were no significant associations
between ghrelin and insulin resistance factors (Table 4).
Comparison of Insulin Resistance in Low, Medium and
High Ghrelin Groups
After dividing volunteers in to three groups based on the ghrelin
tertile, general linear model (multivariative analysis) was used for
the comparison of insulin resistance between low, medium and
high ghrelin groups. For insulin, HOMA-IR, HOMA- b and
QUICKI there was no significant difference between low
and medium ghrelin level or medium and high ghrelin levels but
significant difference was evident between low and high ghrelin
level (p value = 0.003, 0.01, 0.00 and 0.02 respectively). Figure 1
shows the mean and 95% confidence interval for mean of insulin,
HOMA-IR, HOMA-b and QUICKI in high, medium and low
ghrelin groups.
Comparison of Ghrelin Level between Diabetic and Non-
diabetic Subjects
Repeating the analysis after excluding the volunteers who report
a history of diabetes and volunteers who had fasting blood glucose
more than 7 mmol/L, no significant changes in the results were
present.
Table 1. Biochemical and body composition characteristics1.
Entire Cohort Women Men
(n=2063–2085) (n=1571–1584) (n =492–501)
Mean (SD) Mean (SD) Mean (SD)
Age (y) 42.92 (12.8) 43.75 (12.1) 40.29 (14.3)
Weight (kg) 73.64 (15.8) 69.93 (14.2) 85.41 (15.1)
Height (cm) 165.51(8.4) 162.26 (5.9) 175.81 (6.6)
BMI (kg/m2) 26.82 (5.1) 26.57 (5.2) 27.61(4.5)
Waist (cm) 92.13 (14.7) 90.49 (14.6) 97.36 (13.8)
Hip (cm) 101.23 (11.8) 101.65 (12.2) 99.90 (10.0)
Body fat (%) 35.01 (9.1) 37.95 (7.4) 25.66 (7.5)
Trunk fat (%) 37.23 (9.3) 39.30 (8.5) 30.66 (8.8)
Android fat (%) 42.54 (10.9) 44.27 (10.3) 37.03 (10.8)
Gynoid fat (%) 41.17 (9.6) 44.98 (6.4) 29.09 (7.8)
Glucose (mmol/L) 5.11 (0.8) 5.07 (0.8) 5.26 (0.8)
Total Cholesterol(mmol/L) 5.17(1.1) 5.21 (1.0) 5.04 (1.1)
HDL-Cholesterol(mmol/L) 1.46 (0.4) 1.54 (0.4) 1.21 (0.3)
LDL-Cholesterol(mmol/L) 3.14 (0.9) 3.12 (0.9) 3.18 (0.9)
1All values are means 6 Standard Deviations (SDs).
doi:10.1371/journal.pone.0045657.t001
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Association between Fasting Ghrelin and Age and HDL-
cholesterol
Pearson correlation analyses showed no significant relationship
between circulating ghrelin level and body composition charac-
teristics, either in the total cohort or in the males and females
separately. There was a positive correlation between fasting
ghrelin level and age in the entire cohort (r = 0.08 and p = 0.00)
and in females (r = 0.12 and p = 0.00) but not in males (r =20.02,
p = 0.72). No association was found between circulating ghrelin
level and HDL-cholesterol.
Discussion
The major finding in the present study is that circulating fasting
ghrelin level is negatively correlated with insulin resistance and
beta cell function in our CODING study. These findings were
consistent using both HOMA and QUICKI as indices of insulin
resistance. More importantly, our results indicate that the
association of ghrelin with insulin resistance and secretion is
independent of age, body composition and circulating HDL
cholesterol. To our knowledge this is the largest study to evaluate
the effect of ghrelin on insulin resistance, with the most
comprehensive controls for major confounding factors, in the
general population.
A number of experimental studies have evaluated the effect of
ghrelin on insulin secretion in humans. Broglio et al. and Tong
et al. showed that acute administration of ghrelin induced
inhibitory effects on insulin secretion. These effects seem to be
dose dependent and non-growth hormone mediated [12,15]. In
patients with metabolic syndrome, ghrelin was inversely correlated
with insulin level and insulin resistance measured by HOMA-IR
[26]. In a cross sectional study, low ghrelin level has been shown to
be associated with type 2 diabetes and insulin resistance in middle-
aged subjects and these associations remained significant after
adjustment for sex, BMI and age [17]. Our findings provide
further evidence that ghrelin level is negatively correlated with
insulin level and resistance.
In pancreatic b-cells, ghrelin can inhibit glucose-induced insulin
release via Gai2-mediated activation of voltage dependent K
+
channels and diminish action potential in b-cells [27]. Moreover,
high ghrelin level may down-regulate growth hormone or its
receptors and decrease insulin secretion secondarily [28]. Ghrelin
receptors have been identified in the pancreas and ghrelin is
produced partly in islet e cells of the pancreas. Therefore the
inhibitory effect of ghrelin on pancreatic b-cells might partly be
due to paracrine mechanisms [15,29]. Lower insulin resistance
might be a compensatory response to decreased insulin level to
maintain blood glucose within a normal range.
In contrast, there are some studies that did not report any
association between ghrelin level and insulin resistance. A group in
Sweden did not observe association between ghrelin level and
insulin sensitivity measured by euglycemic hyperinsulinemic clamp
in 104 subjects after adjustment for fat free mass [19].
Measurement of insulin resistance with euglycemic hyperinsulin-
emic clamp was certainly good. However, the sample size was very
small compared with our sample size. On top of that the older age
Table 2. Biochemical characteristics of data not normally distributed.
Variables Entire Cohort Female Male
Median Min-Max Median Min-Max Median Min-Max
Ghrelin (ng/L) 194.05 0.74–2339.95 193.44 0.74–2329.09 195.97 2.12–2339.95
Insulin (pmol/L) 55.90 14.40–272 55.55 14.40–272 56.95 14.40–270
HOMA-IR1 1.78 0.41–16.01 1.77 0.41–16.01 1.87 0.41–10.92
HOMA-b2 109.11 12.96–3801.3 111.16 12.96–3801.3 102.52 13.84–1382.29
QUICKI3 0.35 0.26–0.45 0.35 0.26–0.45 0.35 0.27–0.45
Triglyceride (mmol/L) 1.01 0.23–5.88 0.98 0.23–5.88 1.16 0.31–5.54
1HOMA-IR: Homeostatic Model Assessment of Insulin Resistance.
2HOMA-b: Homeostatic Model Assessment of b cell function.
3QUICKI: Quantitative Insulin-sensitivity Check Index.
doi:10.1371/journal.pone.0045657.t002
Table 3. Partial correlation of ghrelin with insulin resistance
indexes after controlling for age, Percentage of trunk fat and
HDL-cholesterol.
Entire Cohort Female Male
r P r P r P
Glucose 0.00 0.99 0.01 0.75 20.03 0.52
Insulin 20.09 0.00* 20.07 0.00* 20.11 0.02*
HOMA-IR 20.08 0.00* 20.06 0.01* 20.10 0.02*
HOMA-b 20.10 0.00* 20.09 0.00* 20.09 0.04*
QUICKI 0.08 0.00* 0.06 0.01* 0.10 0.02*
*P value ,0.05.
doi:10.1371/journal.pone.0045657.t003
Table 4. Partial correlation analyses of ghrelin with physical





r P R P
Glucose (mmol/l) 0.00 0.98 0.01 0.81
Insulin (pmol/L) 20.08 0.02* 20.06 0.14
HOMA-IR 20.07 0.03* 20.05 0.25
HOMA-b 20.09 0.01* 20.07 0.08
QUICKI 0.07 0.04* 0.05 0.26
*P value ,0.05.
doi:10.1371/journal.pone.0045657.t004
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in this study could hinder the detecting of signals because of
increased use of medications and other common chronic diseases.
In a longitudinal study with 5.1 year follow up on 201 subjects,
glucose tolerance and baseline fasting ghrelin level were measured.
They found that fasting ghrelin levels failed to predict the
development of glucose intolerance or type 2 diabetes [20]. The
major concern for this study is that ghrelin is only one of the many
factors affecting the development of insulin resistance and type 2
diabetes, so the possible effect of ghrelin on insulin resistance
cannot be excluded.
Also, there are studies that found a positive association between
ghrelin level and insulin resistance. Vestegard et al reported
increased insulin resistance in 6 healthy men and eight hypopi-
tuitary men on stable replacement therapy with growth hormone
and hydrocortisone after acute administration of ghrelin [16].
Similarly, acute administration of ghrelin in 10 patients who had
the total gasterectomy and truncal vagotomy, reduced insulin
mediated glucose disposal rate [30]. Because of the small sample
size the results of these studies were only suggestive.
Our results, together with the results from others, indicate that
there is a very wide range of ghrelin concentration in the
population. The large standard deviation of circulating ghrelin
would require a very large sample size to achieve the statistical
power to detect the effect of ghrelin on insulin resistance and other
phenotypes. This factor has to be considered since most of the
previous studies seemed to be under power because of the small
sample size which could lead to false positive or false negative
results.
As the only known orexigenic gut hormone, the role of ghrelin
in the development of human obesity is still unclear. Data from
animal studies indicate that ghrelin induces the accumulation of
adipose tissue [31]. However, cross sectional studies in humans
reported negative correlation between ghrelin and adiposity [32].
In our current study we did not find significant association
between fasting ghrelin levels and any adiposity phenotype.
Detailed information will be available in another paper from our
laboratory.
Effect of age on circulating ghrelin is still unclear. Paik and
Thoshinai reported an inverse correlation between ghrelin and age
[33,34] whereas Cummings et al. reported a positive correlation
between ghrelin level and age and they suggest that rising ghrelin
levels could play a role in the effect of aging on increasing body fat
[35]. In the present CODING study a positive correlation was
observed between circulating ghrelin and age. As indicated in the
Figure 1. Error bars show the mean and 95% confidence interval for mean of insulin (A), HOMA-IR (B), HOMA-b (C) and QUICKI (D)
in high, medium and low ghrelin groups.
doi:10.1371/journal.pone.0045657.g001
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analysis, the effect of age on ghrelin has been properly controlled
in the present study.
In postmenopausal women, insulin resistance increases likely
due to the reduced levels of sex hormones and physical activity and
increased body fat [36,37,38]. Several studies explored the effect of
menopause on ghrelin level. Purnell et al. reported that
menopausal status or hormone replacement therapy do not have
any effect on the ghrelin levels [39]; while Soni et al. found that
estrogen hormone therapy can decrease ghrelin level and
discontinuing it can increase ghrelin level in post-menopausal
women [40]. In our study we did not see any significant difference
in ghrelin level between premenopausal and postmenopausal
women. However, we found a significant association between
ghrelin and insulin resistance only in premenopausal women and
not in postmenopausal women. The factors involved in the
absence of relationship between circulating ghrelin and insulin
sensitivity in postmenopausal women could be complicated by
many factors including reduced level of sex hormones and possibly
use of medications.
Previous studies have reported that ghrelin can bind to HDL
particles in the blood [41] and HDL cholesterol level might have
some effect on the measurement of ghrelin [39]. However, in our
CODING study no significant association between circulating
ghrelin and HDL-cholesterol was found.
To control the potential effect of diabetes status on the results of
our study all analyses were repeated after volunteers who had
blood glucose more than 7 mmol/L and reported to have diabetes
were excluded. All findings remained significant.
In summary, the relationship between fasting ghrelin level and
insulin resistance was systematically evaluated in the large
CODING study with more than 2000 adult subjects from the
Newfoundland population. To our knowledge this is the largest
general population based study on the relationship between fasting
ghrelin level and insulin resistance. Major confounding factors
including age, gender, menopausal status and HDL-cholesterol
level have been carefully analyzed and properly controlled. With
the strong statistical power we provide reliable evidence that
ghrelin may be a factor that help to reduce insulin resistance at the
population level. This association is absent in the postmenopausal
women. However, because of the nature and limitations of a cross
sectional study, longitudinal study is warranted to fill the
knowledge gap.
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